Eculizumab in AQP4-IgG NMOSD: Efficacy in the Real World and Potential Warning of Meningococcal Vaccines

Neurology. 2024 Nov 12;103(9):e209970. doi: 10.1212/WNL.0000000000209970. Epub 2024 Oct 1.

Authors

Romain Marignier¹, Amy Kunchok¹

Affiliation

¹ From the Service Sclérose en plaques (R.M.), pathologie de la myéline et neuro-inflammation, and Centre de référence des maladies inflammatoires rares du cerveau et de la moelle, Hospices Civils de Lyon, France; and Mellen Center for Multiple Sclerosis (A.K.), Neurological Institute, Cleveland Clinic, Cleveland, OH.

PMID: 39353150
DOI: 10.1212/WNL.0000000000209970

No abstract available

Publication types

Case Reports
Editorial

MeSH terms

Adult
Antibodies, Monoclonal, Humanized* / therapeutic use
Aquaporin 4* / immunology
Female
Humans
Immunoglobulin G*
Male
Meningococcal Vaccines*
Neuromyelitis Optica* / drug therapy
Neuromyelitis Optica* / immunology

Substances

eculizumab
Aquaporin 4
Meningococcal Vaccines
Antibodies, Monoclonal, Humanized
Immunoglobulin G
AQP4 protein, human